益盛药业品牌怎么样 申请店铺

我要投票 益盛药业在人参行业中的票数:157 更新时间:2025-02-23
益盛药业是哪个国家的品牌?「益盛药业」是 吉林省集安益盛药业股份有限公司 旗下著名品牌。该品牌发源于吉林,由创始人张益胜在1997期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力益盛药业品牌出海!通过在本页面挂载益盛药业品牌的产品链接和联系邮箱,可以提高益盛药业产品曝光!跨境电商爆单神器,目前只要100元/年哦~

益盛药业怎么样

从1997年创业至今,十几年的默默耕耘,十几年的风雨兼程,益盛药业从大山深处的一家小型民营企业,成长为中国A股市场的上市公司,先后被认定为国家重点高新技术企业、国家生物医药产业基地骨干企业、国家农业产业化龙头企业;公司获得中华总工会颁发的“全国五一劳动奖状”、被国家外专局指定为“国家非林地人参种植引智示范单位”;2011年,公司又被吉林省政府列入首批人参药食同源试点企业。

诞生于大山深处的益盛药业,以“传承中华文明,服务人类健康”为企业宗旨,秉持“关爱众生,诚信笃实,以人为本,创新为先”的核心理念,确立了“依托长白山优质资源,依靠现代科学技术,打造完整人参产业链”的发展战略,并稳步完成了益盛药业、益盛参业、益盛永泰蜂业三大品牌的战略布局,这三大品牌统一在战略总目标下,构成这一目标的三大支撑。

在药业方面,公司首先集中全部力量,实现在人参、西洋参基础研究上的重大突破,然后将科研成果全面转化为产品优势,再将产品优势快速转化为市场优势。从1997年开始,公司便与吉林大学、天津中医药大学、沈阳医药大学、清华大学、北京大学等全国知名高校、科研机构建立起紧密的技术协作体,从人参根到人参茎叶、人参花、人参果,都开发出了国药准字号的产品,成为医药行业内,首家实现人参全株开发的企业。公司对西洋参的研究也取得丰硕成果,获得两项发明专利,开发出国家五类(原二类)新药“心悦胶囊”,该产品的研发被列为国家十五、十一五科技支撑计划重大项目。

这些以人参、西洋参为主料的产品,在临床应用上,其功效明显优于竞争品种。产品疗效上的优势,迅速转化为市场上的竞争优势。公司在全国建立了30个省级销售部,200多个市级销售部,产品覆盖全国30个省市的2700多家县(区)级以上医疗单位,15000多家乡镇卫生院和卫生所。公司的业绩在14年的时间里,增长了15倍,利税连年增长,对本地区经济社会的发展做出了应有的贡献。

截止2011年底,公司已有11个剂型通过了GMP认证,拥有国药准字号品种116个,其中52个品种被列入国家医保目录,13个品种被列入《国家基本药物目录》,拥有国家中药保护品种2个,独家品种6个。药品治疗范围以心脑血管疾病为主,涵盖了呼吸系统、消化系统、内分泌系统、泌尿系统以及肿瘤、儿科疾病等。公司运用多项核心技术,确保产品品质,赢得了广大医生和患者的高度信赖。

在参业方面,由药业奠定的坚实基础,使公司具备了向人参上游产业进军的条件。自2006年起,公司会同吉林农业大学,按照GAP标准,以机械化、标准化、规范化、集约化的方式,在国内首开“非林地人参种植”的先河。同时,开发出人参专用有机肥,填补了我国没有人参专用有机肥的空白,建成了年生产能力10000吨的有机肥厂和年生产能力3000吨的微生物液肥车间。

在蜂业方面,公司于2011年10月投资控股了集安市永泰蜂业有限责任公司。蜂蜜是人参功能食品加工的重要原料,长白山是中国北方最重要的天然蜜源基地,也是联合国教科文组织指定的“世界自然保留地”,在没有任何污染的原生态环境里,生长着我国北方特有的树种---椴树,蜂蜜中的上品椴树蜜,主要就出产自这一地区。集安永泰蜂业是长白山区最有影响力的蜂制品企业之一,在蜂农中拥有较高威信和良好信誉。控股永泰蜂业,意味着公司实现了对长白山南麓天然蜂蜜资源的相对垄断,既从根本上保障了人参深加工所需的重要原料,又新增了一项独立产业。目前,益盛永泰蜂业已拥有蜂蜜、蜂胶、蜂王浆、蜂花粉4大系列30个品种,正着力开发参、蜜结合的新型功能食品,努力使人参产业链得到有效的延伸。

Since its establishment in 1997, Yisheng Pharmaceutical Co., Ltd. has grown from a small private enterprise deep in the mountains to a listed company in China's A-share market. It has been recognized as a national key high-tech enterprise, a backbone enterprise in the national biomedical industry base, and a national leading enterprise in agricultural industrialization. The company has been awarded by the China Federation of trade unions The "National May 1st Labor Award" was designated as the "national non forest land ginseng planting and intelligence introduction demonstration unit" by the State Administration of foreign affairs; in 2011, the company was listed in the first batch of ginseng drug and food homologous pilot enterprises by the Jilin provincial government. Yisheng pharmaceutical industry, which was born in the depth of the mountain, takes "inheriting Chinese civilization and serving human health" as the enterprise tenet, adheres to the core concept of "caring for all living beings, being honest, practical, people-oriented and innovation first", establishes the development strategy of "relying on the high-quality resources of Changbai Mountain and relying on modern science and technology to build a complete ginseng industry chain", and steadily completes Yisheng pharmaceutical industry and Yisheng The strategic layout of the three brands of Shenye and yishengyongtai bee industry, which are unified under the overall strategic goal, constitutes the three supports of this goal. In the pharmaceutical industry, the company first concentrated all its efforts to achieve a major breakthrough in the basic research of ginseng and American ginseng, then comprehensively transformed the scientific research results into product advantages, and then quickly transformed the product advantages into market advantages. Since 1997, the company has established close technical cooperation with Jilin University, Tianjin University of traditional Chinese medicine, Shenyang University of medicine, Tsinghua University, Peking University and other national famous universities and scientific research institutions. From ginseng root to ginseng stem and leaf, ginseng flower and ginseng fruit, the company has developed the products with the national medicine license, becoming the first enterprise in the pharmaceutical industry to realize the full plant development of ginseng 。 The company has also made fruitful achievements in the research of American ginseng, obtained two invention patents, and developed five kinds of new drugs "Xinyue capsule". The research and development of this product is listed as a major project in the national science and technology support plan of the 15th and 11th five year plan. These products with ginseng and American ginseng as the main materials are superior to the competitive varieties in clinical application. The advantages of product efficacy are rapidly transformed into competitive advantages in the market. The company has established 30 provincial sales departments, more than 200 municipal sales departments, and its products cover more than 2700 county (District) level and above medical units in 30 provinces and cities, and more than 15000 township hospitals and health centers. In the past 14 years, the company's performance has increased 15 times, and its profits and taxes have increased year by year, making due contributions to the economic and social development of the region. By the end of 2011, the company has passed GMP certification in 11 dosage forms, with 116 varieties under the state drug license, 52 of which have been listed in the national medical insurance catalog, 13 of which have been listed in the national basic drug catalog, 2 of which are under the state protection of traditional Chinese Medicine, and 6 of which are exclusive. The medicine treatment scope mainly includes cardiovascular and cerebrovascular diseases, including respiratory system, digestive system, endocrine system, urinary system, tumor, pediatric diseases, etc. The company uses a number of core technologies to ensure product quality and win the high trust of doctors and patients. In terms of participation, the solid foundation laid by the pharmaceutical industry enables the company to have the conditions to march into the upstream industry of participation. Since 2006, the company, together with Jilin Agricultural University and in accordance with gap standards, has been the first to "non forest ginseng planting" in China in the way of mechanization, standardization, standardization and intensification. At the same time, the development of ginseng specific organic fertilizer has filled in the blank of no ginseng specific organic fertilizer in China, and has built an organic fertilizer plant with an annual production capacity of 10000 tons and a microbial liquid fertilizer workshop with an annual production capacity of 3000 tons. In terms of bee industry, the company invested and controlled Ji'an Yongtai Bee Industry Co., Ltd. in October 2011. Honey is an important raw material for processing ginseng functional food. Changbai Mountain is the most important natural honey source base in northern China, and also the "World Natural Reserve" designated by UNESCO. In the original ecological environment without any pollution, there is a unique tree species in northern China - Tilia trees. The top grade Tilia honey in honey is mainly produced in this area. Ji'an Yongtai bee industry is one of the most influential bee products enterprises in Changbai Mountain area. It has high prestige and good reputation among bee farmers. Holding Yongtai bee industry means that the company has achieved a relative monopoly on the natural honey resources at the south foot of Changbai Mountain, which not only fundamentally guarantees the important raw materials needed for the deep processing of ginseng, but also adds an independent industry. At present, Yisheng Yongtai bee industry has 4 series and 30 varieties of honey, propolis, royal jelly and bee pollen. It is striving to develop new functional food combining ginseng and honey, and strive to effectively extend the ginseng industry chain.

本文链接: https://brand.waitui.com/6d0c156ca.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

上海市副市长陈杰:加快建设人工智能“上海高地”,壮大开源社区力量

36氪获悉,2月23日,2025全球开发者先锋大会在上海徐汇召开,上海市副市长陈杰出席开幕式并发表致辞。陈杰指出,面对人工智能快速迭代、模型开源的新趋势,上海将继续发挥超大城市的综合优势,加快建设更具国际影响力的人工智能“上海高地”。进一步完善开源开放生态系统,夯实“语料开放+模型开源”服务体系,不断壮大开源社区力量,推动基础模型、算法和数据资源的共享与开放,构建开放协作、互利共赢的创新环境。(中国基金报)

58分钟前

清华AIR联合水木分子开源DeepSeek版多模态生物医药大模型BioMedGPT-R1

36氪获悉,清华大学人工智能产业研究院(AIR)和北京水木分子生物科技有限公司近日携手推出了升级版的生物医药多模态开源基础大模型BioMedGPT-R1。此前,在2023年,双方合作发布了开源可商用、生物医药多模态百亿参数开源基础大模型BioMedGPT,水木分子发布了自研千亿参数多模态生物医药专业大模型Chat DD-FM和新一代AI驱动药物发现工具Chat DD。这次DeepSeek版ChatDD- R1基座模型也已同步上线ChatDD,赋能生物医药企业的药物研发。

58分钟前

TCL李东生:中国制造未来在海外最大增量大概率来自新兴市场

36氪获悉,TCL&奥林匹克全球合作伙伴签约仪式近日在北京举行。会后,TCL创始人、董事长李东生接受记者采访时表示,当前全球产业链面临转移与重构,持续由全球化向区域化、本土化方向发展。中国制造未来在海外最大的增量空间大概率来自新兴市场,比如巴西等新兴经济体。目前TCL海外制造基地分布在越南、马来西亚、菲律宾、印尼、印度、巴基斯坦、波兰、墨西哥、巴西等九个国家,实现东南亚、南亚、欧洲、北美、南美等各大区域本土化制造布局。未来,会持续关注新兴市场的增长潜力。

58分钟前

深圳:来深毕业生免费7天住升级为15天

为方便各地高校毕业生来深找工作,深圳相继推出“青年驿站”“深梦启航”“深梦扬帆”等“深梦”系列公益活动,为各地来深高校毕业生提供免费7天居住福利,解决他们阶段性、过渡性的居住需求。 2月23日,深圳市政府新闻办召开“打造最好科技创新生态和人才发展环境”新闻发布会。市委科创委办公室主任、科技创新局局长张林在会上透露,深圳为高校应届毕业生来深求职提供免费住宿天数,将从7天延长到15天。 (深圳特区报)

58分钟前

湖南规范互联网医院处方行为:严禁使用AI等自动生成处方

36氪获悉,湖南省医保局近日发布《关于进一步加强基本医疗保障定点零售药店管理的通知》。通知中提到,规范互联网医院处方行为。对互联网医院处方有如下几个措施:①压实实体医疗机构责任。依托实体医疗机构与市级医保部门签订补充协议,强化实体医疗机构的管理责任,因互联网医院违规被解除补充协议的原则上同步解除实体医疗机构医保定点协议,依托的实体医疗机构原则上应为二级及以上医疗机构。②纳入医保管理范畴。在本统筹区提供处方服务的由本市医保中心签协议后公布,跨市州提供处方服务的先征得药店所在地市级医保中心同意,再报省医保中心审定公布。③接入处方流转平台。互联网医院须按规定接入省医保电子处方中心并进行电子处方流转。④明确处方要求。处方行为必须符合行业主管部门管理办法,应与患者或患者家属进行有效、充分的沟通问诊,严禁使用人工智能等自动生成处方。

58分钟前

本页详细列出关于吉韩庄的品牌信息,含品牌所属公司介绍,吉韩庄所处行业的品牌地位及优势。
咨询